Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy

被引:10
作者
Brenet, Esteban [1 ]
Barbe, Coralie [2 ]
Hoeffel, Christine [3 ]
Dubernard, Xavier [1 ]
Merol, Jean-Claude [1 ]
Fath, Lea [4 ]
Servagi-Vernat, Stephanie [5 ]
Labrousse, Marc [1 ]
机构
[1] Robert Debre Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, F-51100 Reims, France
[2] Robert Debre Univ Hosp, Clin Res Unit, F-51100 Reims, France
[3] Robert Debre Univ Hosp, Dept Radiol, F-51100 Reims, France
[4] Univ Hosp Strasbourg, Dept Otorhinolaryngol Head & Neck Surg, F-67000 Strasbourg, France
[5] Inst Godinot, Dept Radiotherapy, F-51100 Reims, France
关键词
head and neck neoplasm; diffusion-weighted magnetic resonance imaging (MRI); recurrence; chemo-radiotherapy; POSITRON-EMISSION-TOMOGRAPHY; FOLLOW-UP; LARYNGEAL PRESERVATION; INDUCTION CHEMOTHERAPY; TREATMENT RESPONSE; CANCER PATIENTS; FDG-PET; RADIOTHERAPY; COEFFICIENT; CETUXIMAB;
D O I
10.3390/cancers12051234
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumor residue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assess the predictive capacity of pre-treatment diffusion-weighted MRI for persistent tumor residue post-CRT. Materials and Method: A single center cohort study was performed in one French hospital. All patients with squamous cell carcinoma receiving CRT (no surgical indication) were included. Two diffusion-weighted MRI were performed: one within 8 days before CRT and one 3 months after completing CRT with determination of median tumor apparent diffusion coefficient (ADC). Main outcome: The primary endpoint was progression-free survival. Results: 59 patients were included prior to CRT and 46 (78.0%) completed CRT. A post-CRT tumor residue was found in 19/46 (41.3%) patients. In univariate analysis, initial ADC was significantly lower in patients with residue post CRT (0.56 +/- 0.11 versus 0.79 +/- 0.13; p < 0.001). When initial ADC was dichotomized at the median, initial ADC lower than 0.7 was significantly more frequent in patients with residue post CRT (73.7% versus 11.1%, p < 0.0001). In multivariate analysis, only initial ADC lower than 0.7 was significantly associated with tumor residue (OR = 22.6; IC [4.9-103.6], p < 0.0001). Among 26 patients without tumor residue after CRT and followed up until 12 months, 6 (23.1%) presented recurrence or progression. Only univariate analysis was performed due to a small number of events. The only factor significantly associated with disease progression or early recurrence was the delta ADC (p = 0.0009). When ADC variation was dichotomized at the median, patients with ADC variation greater than 0.7 had time of disease-free survival significantly longer than patients with ADC variation lower than 0.7 (377.5 [286-402] days versus 253 [198-370], p < 0.0001). Conclusion and relevance: Diffusion-weighted MRI could be a technique that enables differentiation of patients with high potential for early recurrence for whom intensive post-CRT monitoring is mandatory. Prospective studies with more inclusions would be necessary to validate our results.
引用
收藏
页数:15
相关论文
共 59 条
[1]   Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522 [J].
Ang, K. Kian ;
Zhang, Qiang ;
Rosenthal, David I. ;
Nguyen-Tan, Phuc Felix ;
Sherman, Eric J. ;
Weber, Randal S. ;
Galvin, James M. ;
Bonner, James A. ;
Harris, Jonathan ;
El-Naggar, Adel K. ;
Gillison, Maura L. ;
Jordan, Richard C. ;
Konski, Andre A. ;
Thorstad, Wade L. ;
Trotti, Andy ;
Beitler, Jonathan J. ;
Garden, Adam S. ;
Spanos, William J. ;
Yom, Sue S. ;
Axelrod, Rita S. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2940-+
[2]   Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations [J].
不详 .
NEOPLASIA, 2009, 11 (02) :102-125
[3]  
[Anonymous], 1967, PSYCHOM THEORY
[4]   Epidemiology of head and neck cancers: an update [J].
Auperin, Anne .
CURRENT OPINION IN ONCOLOGY, 2020, 32 (03) :178-186
[5]   Guidelines update: Post-treatment follow-up of adult head and neck squamous cell carcinoma: Screening for metastasis and metachronous esophageal and bronchial locations [J].
Blanchard, D. ;
Barry, B. ;
De Raucourt, D. ;
Choussy, O. ;
Dessard-Diana, B. ;
Hans, S. ;
Lafarge, D. .
EUROPEAN ANNALS OF OTORHINOLARYNGOLOGY-HEAD AND NECK DISEASES, 2015, 132 (04) :217-221
[6]   Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].
Bonner, JA ;
Harari, PM ;
Giralt, J ;
Azarnia, N ;
Shin, DM ;
Cohen, RB ;
Jones, CU ;
Sur, R ;
Raben, D ;
Jassem, J ;
Ove, R ;
Kies, MS ;
Baselga, J ;
Youssoufian, H ;
Amellal, N ;
Rowinsky, EK ;
Ang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578
[7]   Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx A Secondary Analysis of a Randomized Clinical Trial [J].
Bonner, James ;
Giralt, Jordi ;
Harari, Paul ;
Spencer, Sharon ;
Schulten, Jeltje ;
Hossain, Anwar ;
Chang, Shao-Chun ;
Chin, Steve ;
Baselga, Jose .
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2016, 142 (09) :842-849
[8]   Cetuximab and Radiotherapy in Laryngeal Preservation Reply [J].
Bonner, James A. ;
Chin, Steve ;
Spencer, Sharon .
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2017, 143 (05) :526-526
[9]   Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].
Bonner, James A. ;
Harari, Paul M. ;
Giralt, Jordi ;
Cohen, Roger B. ;
Jones, Christopher U. ;
Sur, Ranjan K. ;
Raben, David ;
Baselga, Jose ;
Spencer, Sharon A. ;
Zhu, Junming ;
Youssoufian, Hagop ;
Rowinsky, Eric K. ;
Ang, K. Kian .
LANCET ONCOLOGY, 2010, 11 (01) :21-28
[10]   THE VALUE OF FOLLOW-UP IN PATIENTS TREATED FOR SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK [J].
BOYSEN, M ;
LOVDAL, O ;
TAUSJO, J ;
WINTHER, F .
EUROPEAN JOURNAL OF CANCER, 1992, 28A (2-3) :426-430